Unsubstantiated Drug-Price Hikes Identified by ICER

An ICER report examining the top ten drugs with 2020 price hikes found that a staggering seven out of ten had no new clinical findings to justify raising prices. The price of Humira keeps escalating in the United States while decreasing in every other county that has biosimilars. Ever-increasing launch prices compound the impact of these hikes on consumers.

According to David Rind, MD, ICER’s Chief Medical Officer. “Even more concerning, several of these treatments have been on the market for many years, with scant evidence that they are any more effective than we understood them to be years ago when they cost far less. If new data emerge that show a treatment may be more beneficial than what was previously understood, perhaps some level of price increase is warranted. For seven of the ten high-cost drugs we profiled in this year’s report, though, we found that the price increases lacked such justification.”

Read more by clicking here.

(Source: November, 16^th, 2021)